A PHASE II TRIAL OF SACITUZUMAB GOVITECAN (IMMU-132) (NSC #820016) FOR PATIENTS WITH HER2-NEGATIVE BREAST CANCER AND BRAIN METASTASES
ENROLLING
Trial ID:
NCT04647916 Protocol # :
21-531
Phase
II
Disease Sites
Breast
Principal Investigator
Lin, Nancy, U
Site Research Nurses
Campbell, Margaret
Caradonna, Lisa
Cung, Connie
Jeon, Maryangel, H.
Kasparian, Elizabeth
Loeser, Wendy
Macauley, Colleen
Orechia, Meghan
Patel, Nikita
Roche, Kathleen, A.
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #21-531
21-531